Hofstetter A, Friesen A, Bishop-Freudling G B, Vergin H
Fortschr Med. 1982 Jun 3;100(21):1017-20.
Plasma and prostatic fluid concentrations of co-tetroxacine (TXP/SDZ) were investigated on 12 patients with subacute or chronic prostatitis. Co-tetroxacine was given perorally, 2 x 2 tabl. daily. - Tetroxoprime-(TXP-)concentrations in prostatic fluid were 4.2 micrograms/ml and 4.5 micrograms/ml 3 and 6 hours after peroral application (days 2 and 3) respectively. Compared to the concentrations of TXP in the systemic fluid there was an increase by the factor 3 to 4.3. - The corresponding concentrations of sulfadiazine (SDZ) in prostatic fluid were 11.6 micrograms/ml and 10.0 micrograms/ml - i.e. 62-70% of the plasma concentrations.
对12例亚急性或慢性前列腺炎患者的血浆和前列腺液中co - tetroxacine(TXP/SDZ)浓度进行了研究。co - tetroxacine口服给药,每日2次,每次2片。口服给药后3小时(第2天)和6小时(第3天)前列腺液中Tetroxoprime -(TXP -)浓度分别为4.2微克/毫升和4.5微克/毫升。与全身液体中TXP浓度相比,增加了3至4.3倍。前列腺液中磺胺嘧啶(SDZ)的相应浓度为11.6微克/毫升和10.0微克/毫升,即血浆浓度的62 - 70%。